Navigation Links
Copying nature could save us energy, study shows

New technologies that mimic the way insects, plants and animals overcome engineering problems could help reduce our dependence on energy, according to new research published in the Royal Society journal Interface.

When faced with engineering difficulties, such as lifting a load or coping with extremes of heat, up to 70 per cent of man-made technologies manipulate energy, often increasing the amount used, in order to resolve the problem.

However, new research which has compared how nature and man-made technologies overcome similar problems has shown that only 5 per cent of natural 'machines' rely on energy in the same way.

Instead, insects, plants, birds and mammals rely on the structure and organisation of their body parts and behaviour; the solutions to problems are already built in.

"An example might be a hammer," said Professor Julian Vincent from the University of Bath who led the research .

"A man-made hammer has a very heavy head, so that it is heavy to carry around and lift but can do a lot of work with one hit. It relies on inertia.

"But the woodpecker's hammer, its head, relies on speed. It is very light to carry around, and functions rather like a whip, with the heavier body moving a small amount, and the lighter head, on its long neck, moving much faster.

"They can each deliver the same amount of impact energy, but they do it in a very different way."

Although mankind has looked to nature for inspiration for generations, 'biomimetic' devices are a relatively recent phenomenon. The stable wing in aeroplanes, Velcro and self-cleaning paint are all simple devices based on natural inspiration.

The Centre for Biomimetic and Natural Technologies at the University of Bath is helping extend this principle to more advanced engineering challenges.

Researchers are currently looking at the desert cockroach (to develop a new kind of dehumidifier technology), insect sense organs (for
'"/>

Source:University of Bath


Page: 1 2

Related biology news :

1. Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients
2. Bioelectronic ‘signatures?hold key to DNA mutations
3. The circadian clock: Understanding natures timepiece
4. Scientists map the world for nature conservation
5. Brain Scan Study of Smokers Reveals Signature of Craving
6. Scientists to mimic nature for newest cancer drugs
7. Researchers create functioning artificial proteins using natures rules
8. Eleven gene signature reliably predicts cancer prognosis
9. Scientists and engineers apply natures design to human problems
10. Getting close to nature is good for you
11. Phenotype is influenced by nature, nurture and noise

Post Your Comments:
(Date:11/20/2009)...Toxic dust: Toxins in coal-tar-based sealcoats in ...use dust, according to a USGS study. PAHs or pol... found in oil, coal and tar deposits, and can have... often found in house dust; however, the specific ...searchers found that dust from indoor areas near p...
(Date:11/20/2009)... obstructive pulmonary disease (COPD), a respirato... emphysema, is the fourth leading cause of death w...hile researchers have yet to find any real treatme...itute at The University of Western Ontario in Lond... gain new insight into the disease. , Parrag...
(Date:11/19/2009)... Leaf-cutter ants, which cultivate fungus for foo...ew one to add to the list: the ant farmers, like t... bacteria to make their gardens grow. The finding,...nce , documents a previously unknown symbiosis bet...ow leaf-cutter ants have come to dominate the Amer...
Breaking Biology News(10 mins):From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Gaining a better picture of lung disease 2Like humans, ants use bacteria to make their gardens grow 24th Annual Henry Schein Think Pink Practice Pink Campaign Coincides With Breast Cancer Awareness Month 60383 14th Annual Henry Schein Think Pink Practice Pink Campaign Coincides With Breast Cancer Awareness Month 60383 24th Annual Henry Schein Think Pink Practice Pink Campaign Coincides With Breast Cancer Awareness Month 60383 3Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 5865 1Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 5865 2Children 26apos 3Bs Hospital Physician Honored for Research 60381 1Children 26apos 3Bs Hospital Physician Honored for Research 60381 2Children 26apos 3Bs Hospital Physician Honored for Research 60381 3
...vaccine against HIV infection have been given a mu...obal HIV/AIDS Vaccine Enterprise,s,scientific stra...le,open-access global health journal PLoS Medicin...ternational alliance of,independent agencies and o...research. In June 2004, the G8 countries endorsed ...
...won a £261,000 grant to use the latest software to... stop influenza and some other diseases from repli... comes at a time when fears are rising that an inf...ld kill thousands of people. , Professor Ian Will...ork in April on a project that could help pharmace...
...t microarray-based experiments,reproductibility, ...st,these results? If I redo the same experiment in...H recently demonstrated that microarrays experime...gree of reproducibility , as long as standardized ...the scientific community (and the microarrays prod...
Other Biology News:A much-needed shot in the arm for HIV vaccine development 2A much-needed shot in the arm for HIV vaccine development 3Computers to be used to find blueprint for new influenza drug 2Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible 2Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible 3
(Date:11/19/2009)...ople would like to be able to charge their cell ph...t too often. A recent discovery made by UC San Die...upercapacitors that could do just this. , In re...rs , Prabhakar Bandaru, a professor in the UCSD De...along with graduate student Mark Hoefer, have foun...
(Date:11/19/2009)...BLAUVELT, N.Y., Nov. 19 Dr. Mate H...tract, responds to a press release issued on Novem...an company for making false and self-serving state...es. ,, Dr. Hidvegi stated from his office in B...t research on Avemar does not apply to AveULTRA, ...
(Date:11/19/2009)...BETHESDA, Md., Nov. 19 S... in biotechnology for diabetes therapy, and a prov...es to food, supplement, biotechnology and pharmace...uesday,s Annual Meeting of Shareholders. ,, At ...(Nasdaq: SPEX ) elected the following members to ...
(Date:11/19/2009)...MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeuti...tient in a randomized Phase 2B study of AEG35156, ...lopment for multiple oncology indications. ,, T... 2 Study of the X-Linked Inhibitor of Apoptosis (X...High-dose Cytarabine and Idarubicin in AML Followi...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...ous Guidance for 2007, MADISON, N.J., Jan. 17 Qu...tion,s leading provider of diagnostic,testing, inf...rt results,for the fourth quarter and year ended D...r 2008 on February 21, 2008, instead of the previo...s rescheduling its report of fourth quarter and fu...
...., Jan. 17 Peptimmune, Inc., a privately,held bio...d a first close,of $8.2 million of a Series D pref...ed by New Enterprise Associates, MPM Capital, Hunt...on Valley Bank Capital, as well as,certain other i... Company,expects a second close in Q2/2008, which ...
... Support a Marketing Authorization Application in ...OUSTON, Jan. 17 Agennix Incorporated announced to...A) has approved the design of,a single, pivotal, P...errin alfa, in combination with chemotherapy as fi... lung cancer (NSCLC) under the,Special Protocol As...
Other Biology Technology:Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results 2Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results 3Peptimmune Announces First Close of Series D Private Financing 2Peptimmune Announces First Close of Series D Private Financing 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5
...plications for the use of small interfering RNA (s... RNA interference (RNAi) pathway have generated tr...ology fields. siRNA for experimental use can be sy...ally, and then transfected into the target cells i...
...ogical data hidden in your samples with eArray and...acturing allows you to create your own microarray ...Design at your own pace and receive delivery of yo...is a secure, online array creation application too...
...les are used to study co-translational and initial...sing events such as signal peptide cleavage, membr...n can be examined by the translation of the approp...somal membranes. In addition, processing and glyco...
Mouse Anti-Human Procollagen type I C-terminal propeptide (PICP) Monoclonal Antibody, Unconjugated from AntibodyShop A/S
Biology Products: